2021
INTERIM REPORT

TABLE OF CONTENTS



CORPORATE INFORMATION

E ec ti e directors

(陳力)(

(林潔誠)

Non-e ec ti e directors

(陳連！晢鿏擘祂蔡 / 磚炔⑩邿 T 规螰軉漩礨猰謱剴秬 삹◢寶钀菽 - 斨隀貽禁漩构炕朧髫廚雰瀛臨钀菽馭青貙獸嬂耀華鴕놁되巉꾥

Hong Kong share registrar

54, 183

Principal bankers

1

FINANCIAL HIGHLIGHTS


	Si months ended J ne 30,	
	2021	2020
	RMB'000	RMB'000
	(na dited)	(na dited)
	3,612	3,554
	(3,788)	3,463
A	(63,518)	(64,248)
	(1,999)	(2,247)
	(97,982)	(112,253)
	(1,617)	(1,724)
	(165,292)	(173,455)
	(165,292)	(173,455)
	(2)	(202)
Total comprehensi e e pense for the period	(165,294)	(173,657)

	At J ne 30	At December 31
	2021	2020
	RMB'000	RMB'000
	(na dited)	(a dited)
	152,756	153,244
	874,367	1,045,277
	82,748	106,547
	791,619	938,730
	354,959	359,479
	589,416	732,495

MANAGEMENT DISCUSSION AND ANALYSIS

B siness o er ie

Prod ct pipeline



HMM0111

W 2021 A A 0111 -1 2 -4 -1, 2

Ca tionar Statement req ired nder R le 18A.08(3) of the Listing R les: W

B siness o tlook

2021, -1 2 2 1 W

Ke e ents after the reporting period

30, 2021

Financial re ie

Other income

3.6 30, 2021 3.6 30, 2020,
0.4 30, 2021, 0.4

Other ains and losses

7.3 30, 2021.

Administrative expenses

0.7 63.5 30, 2021 64.2
30, 2020,) 4.0
4.7 2020,)
2.6) 1.3
30, 2020 -19 1.8
2020.

Other expenses

1.6 250,000)
30, 2021 1.7 250,000) 30, 2020
2

Finance cost

2.0 30, 2021 2.2 30, 2020, 2020.

Research and development expenses

	Si months ended J ne 30,			
	2021		2020	
	RMB'000	%	RMB'000	%
	18,564	19.0%	46,565	41.6%
	3,236	.437		

Income tax expense

W[illegible] 30, 2021 [illegible] 30, 2020.

Liq idit and capital reso rces

[illegible] 164.3 [illegible] 30, 2021. A[illegible] 30, 2021, [illegible] 846.9 [illegible].

A[illegible] 30, 2021, [illegible]

Cash operating cost

[illegible]:

	Si months ended J ne 30,	
	2021	2020
	RMB'000	RMB'000
&	90,873	91,247
A[illegible]		
W[illegible]	29,377	27,386
	44,040	48,772
	73,417	76,158
	164,290	167,405

Cash flo s

[illegible] 30, 2021 [illegible] 2020:

	Si months ended J ne 30,	
	2021	2020
	RMB'000	RMB'000
[illegible]	(164,290)	(167,405)
[illegible]	(10,124)	2,871
[illegible]	(5,788)	(3,832)
[illegible]	(4,960)	12,350
[illegible]	(185,162)	(156,016)

Net cash used in operatin activities

[illegible]

[illegible] 30, 2021, [illegible] 164.3 [illegible] 165.3 [illegible] 38.8 [illegible] 37.8 [illegible] 30, 2021 [illegible]

[illegible] 30, 2021, [illegible] 764 [illegible] 23 8.8 [illegible] 30, 2021 [illegible]

Indebtedness

A 30, 2021, 76.3 :

	As of J ne 30, 2021 RMB'000	As of December 31, 2020 RMB'000
	11,599	11,503
	64,692	69,212
	76,291	80,715

30, 2021 . A 30, 2021,

Q alitati e and Q antitati e Disclos res Abo t Market Risk

Currenc Risk

A

5%

5%

5%

5%

	As of J ne 30, 2021 RMB'000	As of December 31, 2020 RMB'000
Impact on profit or loss		
, $	(19,400)	(22,228)
$	(1,967)	(2,210)

Impact onsecash fates snd the an inc deei n to ich conc r(2)ed asseosst the . dollacash fates snd the

[illegible] 30, 2021 [illegible] 0.8 [illegible] 31, 2020 [illegible]

Disclos re nder R les 13.13 to 13.19 of the Listing R les

[illegible] 30, 2021, [illegible] 13.13 13.19 [illegible].

Emplo ees and rem neration policies

A [illegible] 30, 2021, [illegible] 154 [illegible] 30, 2021:

	N mber of emplo ees	Appro imate percentage
[illegible]	73	47%
[illegible]	72	47%
[illegible]	9	6%
[illegible]	154	

O tstanding Share Options Granted nder the Pre-IPO Share Incenti e Scheme

Name or categor of grantee	Date of grant	E ercise price	Vesting Period[1]	N mber of Shares nderl ing options o tstanding as at 1 Jan ar 2021	N mber of options e ercised d ring the Reporting Period	Weighted a erage price of Shares immediatel before the date(s) of e ercise	N mber of options cancelled d ring the Reporting Period	N mber of options lapsed d ring the Reporting Period	N mber of Shares nderl ing options o tstanding as at 30 J ne 2021
Categor 1: Directors									
	4, 2014 - A , 26, 2018	$0.07- 0.49	4 ,	11,921,725	(500,000)	$4.06			11,421,725
, ,	A , 3, 2018	$0.47	4 ,	25,592,405					25,592,405
Categor 2: Emplo ees other than Directors									
	25, 2013 - A , 26, 2018	$0.07- 0.47	4 ,	51,671,543	(1,465,291)	$5.35	(436,404)[2]		49,769,848
Categor 3: Cons ltants									
	12, 2013 - 11, 2018	$0.07- 0.47	1- 4 ,	6,177,000					6,177,000
	Total			**95,362,673**	**(1,965,291)**		**(436,404)**		**92,960,978**

:

(1) 25% 75% 36 12,2013 15, 2016. 12, 2013 10 33% 67% 24 15, 2016 10 12 10

(2) $0.546 $3.666.

O tstanding RSUs Granted nder the Pre-IPO Share Incenti e Scheme

Name	Date of grant	Vesting Period[1]	N mber of Shares nderl ing RSUs o tstanding as of Jan ar 1, 2021	RSUs ested d ring the Reporting Period	RSUs cancelled/ lapsed d ring the Reporting Period	N mber of Shares nderl ing RSUs o tstanding as of J ne 30, 2021
	A 3, 2018	4	3,247,533	(927,876)		2,319,657

:

(1) 48

O tstanding Share Options Granted nder the Post-IPO Share Option Scheme

Name or categor of grantee	Date of grant	Closing price of the Shares immediatel before the date of grant	E ercise price	Vesting Period[1]	N mber of Shares nderl ing options o tstanding as at 1 Jan ar 2021	N mber of options granted d ring the Reporting Period	N mber of options e ercised d ring the Reporting Period	Weighted a erage price of Shares immediatel before the date(s) of e ercise	N mber of options cancelled d ring the Reporting Period	N mber of options lapsed d ring the Reporting Period	N mber of Shares nderl ing options o tstanding as at 30 J ne 2021
Categor 1: Directors											
	8, 2019	$4.83	$4.984	4	12,079,000	3,000,000					15,079,000
	22, 2021	8.89	8.866								
	8, 2019	$8.89	$8.866	4	300,000						300,000
Categor 2: Grantees other than Directors											
	28, 2018	$3.00	$3.000								
	6, 2021	8.89	8.866	4	18,187,194	7,500,000	(137,500)	$4.67	(1,842,741)[2]	(206,270)[3]	23,500,683
Categor 3: cons ltants											
	8, 2019	$8.89	$8.866	4	200,000						200,000
	Total				**30,766,194**	**10,500,000**	**(137,500)**		**(1,842,741)**	**(206,270)**	**39,079,683**

:

(1) 25% 75% 36 10

(2) $3.616 $8.866.

(3) $8.866.

Pledge of assets

A[illegible] 30, 2021, [illegible] (30, 2020:).

F t re Plans for Material In estments and Capital Assets

A[illegible] 30, 2021, [illegible] A[illegible].

Contingent Liabilities

A[illegible] 30, 2021, [illegible] (30, 2020:).

REPORT ON REVIEW OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

TO THE DIRECTORS OF HUA MEDICINE

(

Introd ction

W ( ) 19 40, 30, 2021 34 (34) A 34.

Scope of re ie

W 2410 A (2410) A A A A A

Concl sion

34.

Deloitte To che Tohmats

A 19, 2021

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

A [illegible] 30, 2021

	[illegible]	At J ne 30, 2021 RMB'000 (na dited)	At December 31, 2020 RMB'000 (a dited)
Non-c rrent assets			
[illegible]	11	44,947	49,341
[illegible]	11	66,515	74,177
[illegible]	11	9,384	3,387
[illegible]	12	31,910	26,339
		152,756	153,244
C rrent assets			
[illegible]	12	27,439	13,187
[illegible]	13	846,928	1,032,090
		874,367	1,045,277
C rrent liabilities			
[illegible]	14	56,899	80,794
[illegible]	15	14,250	14,250
[illegible]		11,599	11,503
		82,748	106,547
Net c rrent assets		791,619	938,730
Total assets less c rrent liabilities		944,375	1,091,974
Non-c rrent liabilities			
[illegible]	15	7,248	7,248
[illegible]		283,019	283,019
[illegible]		64,692	69,212
		354,959	359,479
Net assets		589,416	732,495
Capital and reser es			
[illegible]	16	7,209	7,209
[illegible]	16	(669)	(690)
[illegible]		582,876	725,976
Total eq it		589,416	732,495

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

[illegible] 30, 2021

	Attributable to owners of the Company							
	Share capital RMB'000	Treasury shares held in trust RMB'000	Share premium RMB'000	Other reserve RMB'000	Share option reserve RMB'000	Translation reserve RMB'000	Accumulated losses RMB'000	Total RMB'000
At January 1, 2021 (audited)	7,209	(690)	5,899,838	(9,392)	206,387	(453)	(5,370,404)	732,495
Loss for the period (unaudited)							(165,292)	(165,292)
Other comprehensive income for the period (unaudited)						(2)		(2)
Total comprehensive income for the period (unaudited)						(2)	(165,292)	(165,294)
Shares vested under the Share Award Scheme (Note 16(b)) (unaudited)		14	2,478	(14)				2,478
Equity-settled share-based payments (unaudited)			373					373
Transfer of share option reserve upon expiry of share options (Note 16(a)) (unaudited)		7		(7)				
Equity-settled share-based payments (unaudited)					19,364			19,364
At June 30, 2021 (unaudited)	7,209	(669)	5,902,689	(9,413)	225,751	(455)	(5,535,696)	589,416
At January 1, 2020 (audited)	7,209	(729)	5,893,318	(9,353)	147,445		(4,977,270)	1,060,620
Loss for the period (unaudited)							(173,455)	(173,657)
Other comprehensive income for the period (unaudited)						(202)		(202)
Total comprehensive income for the period (unaudited)						(202)	(173,455)	(173,657)
Shares vested under the Share Award Scheme (Note 16(b)) (unaudited)		2	548	(2)				548
Transfer of share option reserve upon expiry of share options (Note 16(a)) (unaudited)		7		(7)				
Equity-settled share-based payments (unaudited)					30,216			30,216
At June 30, 2020 (unaudited)	7,209	(720)	5,893,866	(9,362)	177,661	(202)	(5,150,725)	917,727

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

[illegible] 30, 2021

	Si months ended J ne 30,	
	2021	2020
	RMB'000	RMB'000
	(na dited)	(na dited)
OPERATING ACTIVITIES		
[illegible]	(165,292)	(173,455)
A [illegible] :		
[illegible]	(2,786)	(3,167)
[illegible]	(345)	(60)
[illegible]	6,128	2,277
[illegible]	9,055	10,106
A [illegible]	395	137
[illegible]	1,999	2,247
[illegible]	19,364	30,216
[illegible]	4,958	(12,552)
[illegible]	66	

A [illegible] 34 34379

	Si months ended J ne 30,	
	2021	2020
	RMB'000	RMB'000
	(na dited)	(na dited)
FINANCING ACTIVITIES		
[illegible]	2,018	1,704
[illegible]	(7,806)	(5,536)
NET CASH USED IN FINANCING ACTIVITIES	(5,788)	(3,832)
DECREASE IN CASH AND CASH EQUIVALENTS	(180,202)	(168,366)
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD	1,032,090	1,105,600
[illegible]	(4,960)	12,350
CASH AND CASH EQUIVALENTS AT END OF PERIOD, REPRESENTED BY BANK BALANCES AND CASH	846,928	949,584

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

[illegible] 30, 2021

1. GENERAL INFORMATION AND BASIS OF PREPARATION

1.1 General information

[illegible] 10, 2009, [illegible] 14, 2018 [illegible]. [illegible] 5552, [illegible] 2 [illegible].

1.2 Si nificant events and transactions in the current interim period

[illegible] 2021, [illegible] A [illegible].

1.3 Basis of preparation

[illegible] 34 [illegible] A [illegible] 16 [illegible].

[illegible]

2. PRINCIPAL ACCOUNTING POLICIES

[illegible]

[illegible] (the "Group"), [illegible] 30, 2021 [illegible] 31, 2020.

Application of ne and amendments to IFRSs

[illegible] A[illegible] ("A[illegible]"), [illegible] 1, 2021[illegible]:

A[illegible] 9, A[illegible] 39, [illegible] 7, [illegible] 4 [illegible] 16 [illegible] 2

[illegible] A[illegible] 16 [illegible]-19-[illegible] 30[illegible] 2021[illegible].

[illegible]

3. SEGMENT INFORMATION

[illegible]

[illegible]

4. OTHER INCOME

	Si months ended J ne 30,	
	2021	2020
	RMB'000	RMB'000
	(na dited)	(na dited)
	2,786	3,167
	481	327
	345	60
	3,612	3,554

:

5. FINANCE COST

	Si months ended J ne 30,	
	2021	2020
	RMB'000	RMB'000
	(na dited)	(na dited)
	1,999	2,247
	1,999	2,247

6. LOSS BEFORE TAX

[illegible]:

	Si months ended J ne 30,	
	2021	2020
	RMB'000	RMB'000
	(na dited)	(na dited)
[illegible]	6,128	2,277
[illegible]	9,055	10,106
A [illegible]	395	137
[illegible]	15,578	12,520
[illegible]-19-[illegible]	345	60
[illegible] ( )	1,617	1,724
[illegible] ([illegible]):		
[illegible]	66,009	60,624
[illegible]	5,271	1,657
[illegible]	19,364	30,216
	90,644	92,497
A [illegible]	680	680
[illegible]	263	785

[illegible]:

[illegible] 2021, [illegible] ($.) 0.25 [illegible] (1,617,000) (2020: $0.25 [illegible] 1,724,000))[illegible] 2 [illegible] A.

9. DIVIDENDS

[illegible]

10. LOSS PER SHARE

[illegible]:

[illegible]:

	Si months ended J ne 30,	
	2021	2020
	RMB'000	RMB'000
	(na dited)	(na dited)
[illegible]	(165,292)	(173,455)

10. LOSS PER SHARE (Contin ed)

:

	Si months ended J ne 30,	
	2021	2020
	(na dited)	(na dited)
W	955,092,759	948,878,897

30, 2021 2020

30, 2021 2020

11. EQUIPMENT, RIGHT-OF-USE ASSETS AND INTANGIBLE ASSETS

30, 2021, 1,885,000 ( ) (, 30, 2020: 1,498,000 ( )) 149,500 73,500, 76,000. 30, 2021 44,947,000 ( ) (31, 2020: 49,341,000 ( )).

30, 2021, 1,994,000 ( ) 1,994,000 ( ). 30, 2021 66,515,000 ( ) 76,291,000( ),

-19 16.46 345,000 (, 30, 2020: 60,000)

1 6,391,000)

8.

12. PREPAYMENTS AND OTHER RECEIVABLES

	At June 30, 2021 RMB'000 (unaudited)	At December 31, 2020 RMB'000 (audited)
[illegible]	16,824	2,146
[illegible]		
[illegible]	1,810	1,814
[illegible]	4,194	4,194
[illegible]	26,976	21,910
[illegible]	262	704
[illegible]	1,120	287
[illegible]		
[illegible]	7,423	8,236
[illegible]	740	235
	59,349	39,526
A[illegible]		
[illegible]	27,439	13,187
[illegible]	31,910	26,339
	59,349	39,526

13. BANK BALANCES AND CASH

[illegible] 0.001% [illegible] 1.95 % [illegible] 30, 2021 ([illegible] 31, 2020: [illegible] 0.001% [illegible] 2.3% [illegible]

14. TRADE AND OTHER PAYABLES

	At June 30, 2021 RMB'000 (unaudited)	At December 31, 2020 RMB'000 (audited)
[illegible]	23,790	25,821
[illegible]	17,305	32,285
[illegible]	5,812	
[illegible]	3,392	4,179
[illegible]	1,493	12,383
[illegible]	5,107	6,126

15. DEFERRED INCOME

	At June 30, 2021 RMB'000 (unaudited)	At December 31, 2020 RMB'000 (audited)
[illegible]		
[illegible]	14,250	14,250
[illegible]	7,248	7,248
	21,498	21,498

16. SHARE CAPITAL (Contin ed)

30, 2021 :

	N mber of treas r shares	US$	Sho n in the condensed consolidated statement of financial position as RMB'000
31, 2020 ( ) ( )	100,910,741	100,910	690
( )	(1,965,291)	(1,965)	(14)
( )	(927,876)	(928)	(7)
30, 2021 ( ) ( )	98,017,574	98,017	669

:

( ) A , 26, 2018, ( ) ( ), , 17). A 30, 2021, 98,017,574 $98,017 669,000) (31, 2020: 100,910,741 $100,910 690,000)) 95,697,917 (31, 2020: 97,663,208) 2,319,657 (31, 2020: 3,247,533) .

( ) 30, 2021, 1,965,291 $1.59 2,478,000.

(a) 30, 2021, 927,876 $0.001

17. SHARE-BASED PAYMENT TRANSACTIONS

Equity-settled share option scheme of the Company

On May 5, 2013, the Company adopted a share option scheme (the "2013 Share Option Scheme") for the purpose of providing incentives to directors, and eligible employees of the Group. Under the 2013 Share Option Scheme, the Board of Directors of the Company may grant options to eligible employees, including directors of the Company and its subsidiaries, to subscribe for shares in the Company. The 2013 Share Option Scheme will remain in force for 10 years from May 5, 2013. The maximum number of shares in respect of which options may be granted under the 2013 Share Option Scheme is 117,000,000 shares.

On April 26, 2018, the Company adopted a share option scheme (the "2018 Share Option Scheme"). The

17. SHARE-BASED PAYMENT TRANSACTIONS (Contin ed)

Equit settled share option scheme of the Compan (Continued)

(2)

Categories	Date of grant	N mber of options o tstanding at J ne 30, 2021	E ercise price per share
	8, 2019 – 22, 2021	15,079,000	$4.984 – 8.866
	8, 2019	300,000	$8.866
	28, 2018 – 6, 2021	23,500,683	$3.000 – 8.866
	8, 2019	200,000	$8.866

(3) 10 25% 75% 36 12, 2013 15, 2016. 12, 2013 10 33% 67% 24 15, 2016 10 12 10,519,300 8, 2019 0301 ( ). 11, 2019, 10,519,300 11, 2019 0301 .

17. SHARE-BASED PAYMENT TRANSACTIONS (Contin ed)

Equit settled share option scheme of the Compan (Continued)

[illegible] 30, 2021:

Categor	Option t pe	O tstanding at December 31, 2020	Granted d ring the period	E ercised d ring the period	Forfeited d ring the period	Lapsed d ring the period	O tstanding at J ne 30, 2021
Categor 1: Directors							
[illegible]	[illegible]	11,921,725		(500,000)			11,421,725
	[illegible]	12,079,000	3,000,000				15,079,000
		24,000,725	3,000,000	(500,000)			26,500,725
[illegible]	[illegible]	25,592,405					25,592,405
[illegible]	[illegible]	300,000					300,000
		25,892,405					25,892,405
	[illegible]	49,893,130	3,000,000	(500,000)			52,393,130
Categor 2: Emplo ees							
	[illegible]	51,671,543		(1,465,291)	(436,404)		49,769,848
	[illegible]	18,187,194	7,500,000	(137,500)	(1,842,741)	(206,270)	23,500,683
	[illegible]	69,858,737	7,500,000	(1,602,791)	(2,279,145)	(206,270)	73,270,531
Categor 3: cons ltants							
	[illegible]	6,177,000					6,177,000
	[illegible]	200,000					200,000
	[illegible]	6,377,000					6,377,000
	[illegible]	126,128,867	10,500,000	(2,102,791)	(2,279,145)	(206,270)	132,040,661
[illegible]		84,050,356					95,939,008
[illegible]	[illegible] ($)	3.65	5.00	1.72	4.87	8.87	3.76

17. SHARE-BASED PAYMENT TRANSACTIONS (Contin ed)

Equit settled share option scheme of the Compan (Continued)

30, 2021

	Jan 2021	March 2021	Ma 2021
	$3.29	$3.08	$3.02
	$5.22	$4.83	$4.75
	$5.58	$4.98	$4.89
	73.86%	73.28%	73.12%
	6.08	6.08	6.08
	0.47%	0.94%	0.84%
	0.00%	0.00%	0.00%

30, 2021, 18,710,000 ( ). (, 30, 2020: 28,800,000 ( )).

Restricted stock units

2017, 7,422,975 A 3, 2018. 48 $0.24

17. SHARE-BASED PAYMENT TRANSACTIONS (Contin ed)

Restricted stock units (Continued)

30, 2021 :

	N mber of n ested restricted stock nits
31, 2020 ( )	3,247,533
	927,876
30, 2021 ( )	2,319,657

654,000 ( ) 30, 2021 (, 30, 2020: 1,416,000 ( )).

18. RELATIONSHIP PARTY TRANSACTIONS

( )

:

	Si months ended J ne 30,	
	2021	2020
	RMB'000	RMB'000
	(na dited)	(na dited)
	5,780	5,821
	73	39

OTHER INFORMATION

P rchase, sale or redemption of the Compan 's listed sec rities

30, 2021.

Interim di idend

30, 2021 (30, 2020:).

Use of net proceeds from the Global Offering

14, 2018. 747.2 (5, 2018), W 2022

30, 2021:

	% of se of proceeds	Net proceeds from the Global Offering RMB million	Act al sage p to J ne 30, 2021 RMB million	Un tili ed net proceeds as of J ne 30, 2021 RMB million
	39%	291.4	291.4	
	9%	67.2	35.9	31.3
	27%	201.8	33.5	168.3
	11%	82.2	16.4	65.8
	4%	29.9		29.9
	10%	74.7	74.7	
	100%	747.2	451.9	295.3

Disclos re of interests

Directors and chief executives' interests and/or short positions in the Shares, underl in Shares and debentures of the Compan or an of its associated corporations

A 30, 2021, 352 A 10

Name of Director	Nat re of interest	N mber of Shares	Appro imate percentage of shareholding in the Compan
	[1]	25,220,690 ( )	2.39%
	[2]	29,000,725 ( )	2.74%
	[3]	10,000,000 ( )	0.94%
	[4]	3,633,178 ( )	0.34%
	[5]	30,758,522 ( )	2.91%
	[6]	125,088,960 ( )	11.85%
	[7]	150,000 ( )	0.01%
	[8]	8,571,420 ( )	0.81%
	[9]	108,486 ( )	0.01%
W A	[10]	24,000 ( )	0.01%

:

(1)

(2)

(3) 10 A 2019, 100,000 1 100% 10,000,000

(4) A 2005 A 2005

(5)

(6) A A A

(7)

(8) A A

(9)

(10)

(11) 30, 2021.

(12)

30, 2021, 352

Substantial shareholders' interests and short positions in the Shares, underl in Shares and debentures of the Compan

A 30, 2021, 336

Name of Shareholders	Capacit /nat re of interest	N mber of Shares held[9]	Appro imate percentage of shareholding in the Compan
A .[1]		125,088,960( )	11.85%
A .[1]		125,088,960( )	11.85%
A [1]		125,088,960( )	11.85%
A [1]		125,088,960( )	11.85%
W [1]		125,088,960( )	11.85%
A .[2]		103,475,595( )	9.80%
[2]		103,475,595( )	9.80%
[3][4]		73,806,914( )	6.99%
[3][4]		73,756,914( )	6.99%
[3][4]		73,756,914( )	6.99%
A [3][4]		73,756,914( )	6.99%
[3][4]		73,756,914( )	6.99%
[3][5]		73,757,373( )	6.99%
.[3][5]		73,757,373( )	6.99%
A .[3][5]		73,757,373( )	6.99%
[3][5]		73,757,373( )	6.99%
W .[6]		74,029,635( )	7.01%
W .[6]		74,029,635( )	7.01%
W ( ) .[6]		74,029,635( )	7.01%
W ( ) .[6]		74,029,635( )	7.01%
W A [6]		74,029,635( )	7.01%
W A .[6]		74,029,635( )	7.01%
[7]		105,474,543( )	9.99%
( ) [7]		105,474,543( )	9.99%
[7]		105,474,543( )	9.99%
[8]		25,220,690( )	2.39%
		29,000,725( )	2.74%
		10,000,000( )	0.94%

:

1.

2.

3. 4.08%
3.57%

4.11%

0.20%

11.91%

4.

6.99%

5. [illegible]

[illegible] 6.99% [illegible]

6. [illegible]

Sec rities transactions b the Directors

30, 2021.

Corporate go ernance

Changes to information in respect of the Directors

腾盛博藥生物科技有限公司
(: 2137) 22, 2018, 13, 2021.

( ) A
2018, A A 17, 2021.

A
( ) 2021, A A .

(A)
( ), 2021, A A .

騰盛博藥生物科技有限公司(股份代號: 2137)於二零二一年三月13日,

12, 2015,

15, 2021

(股份代號: 2616)於二零二一年三月9日,

8, 2021,

13.51(1)

Re ie of interim report

30, 2021

2410

(2410.)

30, 2021,